Cytarabine (ARA-C) is a chemotherapeutic agent used in the treatment of hematologic malignancies. Although infusion reactions are generally observed with ARA-C, IgE and non-IgE-mediated hypersensitivity reactions have also been reported. Anaphylaxis was observed on the 3rd dose of ARA-C treatment in a 17-year-old patient diagnosed with acute myeloid leukemia. There was no alternative treatment option for his malignant disease, and we decided to conduct ARA-C desensitization. We would like to describe a successful desensitization protocol in a pediatric patient who experienced anaphylaxis during ARA-C infusion.